News
New investment in the research against Ewing’s sarcoma
Aptadel Therapeutics receives half a million dollars for a preclinical research program against Ewing’s sarcoma.
A new triple combination of inhibitors based on precision medicine emerges as a potential new treatment for Malignant Peripheral Nerve Sheath Tumors
A multicenter collaboration leaded by the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Germans Trias i Pujol Research Institute (IGTP) identified a potential new treatment for an aggressive sarcoma arising in the nerves. The findings have been published in the journal Clinical Cancer Research.
The first joint Conference on Translational Medicine and Regenerative Medicine is held at the Bellvitge Campus
The conference fostered interactions between both research areas to generate new synergies and nurture existing ones.
Multicentre study reaffirms need for vaccination in adults to protect against Invasive Pneumococcal Disease
The study underscores the importance of increasing vaccination in adults to prevent invasive pneumococcal disease, especially in risk groups (older adults and/or those with comorbidities).
There is a need to continue developing and improving pneumococcal vaccines to expand their coverage, given the great capacity of these pathogens to adapt.
Step forward in the understanding of Ewing sarcoma
IDIBELL researchers identify key factors in Ewing’s sarcoma metastasis
Dr. Fernando Fernández Aranda and Dr. Esteve Fernández, distinguished with ICREA Academia grants to promote research
Two IDIBELL researchers receive financial support to consolidate and enhance the internationalization of their research
New perspectives on prostate cancer: the identification of dietary and microbial metabolites could be key in prevention
This large-scale nutrimetabolomic analysis, one of the most extensive to date, underscores the relevance of dietary factors and the gut microbiome in prostate cancer risk.
The study has been led by the Bellvitge Biomedical Research Institute (IDIBELL), the University of Barcelona and the CIBER on Frailty and Healthy Ageing (CIBERFES).
A multicenter clinical trial has evaluated the efficacy and safety of extended antibiotic infusion in febrile neutropenia
A Bellvitge research team has conducted a randomized clinical trial in hematological patients with febrile neutropenia to assess the efficacy of extended infusion of beta-lactam antibiotics
The results show that extended perfusion may be useful in combating some infections, but do not support the introduction of this technique into daily clinical practice for the empirical treatment of febrile neutropenia.
IDIBELL, Bellvitge Hospital and the Josep Carreras Institute discover a key mechanism in the recovery of kidney transplant function
They have described a cause why kidney progenitor cells sometimes can’t repair damaged tissues
The study has been published in the American Journal of Transplantation, the journal with the highest impact on transplantation